Back

Tears Rewired: Innovations in Neuromodulatory Treatments for Dry Eye Disease

Traditional therapies for dry eye disease (DED) often fall short of addressing the complex pathophysiology of the condition, particularly dysfunction within the lacrimal functional unit (LFU). With the recent approval of both a neuromodulatory device and two neuromodulatory pharmaceuticals, clinicians now have access to innovative treatments that stimulate natural tear production and offer comprehensive disease control. Join two leading DED experts in this on-demand video as they discuss: The pathophysiology of DED, including the role of the LFU and its neural network Evidence-based diagnostic strategies The role and limitations of traditional DED therapiesA 2D animation illustrating the mechanisms of action of neuromodulatory treatments for DEDRecent safety and efficacy data for neuromodulatory therapies Practical guidance on integrating these novel therapies into real-world patient care. This program offers timely, clinically relevant insights to help you deliver more effective, personalized care for patients with DED.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 0.75 creditsAMA PRA Category 1 Credit™Up to 0.75 creditsNursingUp to 0.75 creditsOptometryUp to 0.75 creditsPharmacyUp to 0.75 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

Free

Reported to ACCME by the provider

  • On-demand / recorded video
  • Credit · Up to 0.75 credits
  • Commercial Support
  • Released
    Oct 17, 2025
  • Last day to claim credit
    Oct 17, 2026 6 days left